LEVEL OF GLYCATION END PRODUCTS AND GALACTIN-3 IN PATIENTS WITH CHRONIC HEART FAILURE AND ATRIAL FIBRILLATION IN DEPENDENCE ON THE AGE AND RENAL FUNCTIONAL

Olexander Kuryata, Muhammad Muhammad, Olga Mytrokhina

Abstract


Aim. To analyze the changes of advanced glycation end products (AGE) and galectin-3, their relationship in patients with chronic heart failure (CHF) and atrial fibrillation (AF), depending on the renal functional and age.

Material and methods. 30 patients with CHF II-III FC according to the classification of the New York Heart Association (NYHA) with preserved systolic function were examined (EF >45 %, mean 58.73 [45.38, 88.00] %), mean age 66.86 [46.00, 85.00] years who were on treatment in the Regional Hospital after
I.I. Mechnikov. Men accounted for 60 % (18 people), women - 40 % (12 people). All patients were with AF: 17 (56.7 %) - with a permanent form, 13 (43.3 %) - with persistent. The serum creatinine level was determined and the GFR was calculated by CKD-EPI. The level of galectin-3 in the blood was determined by immunofermentive analis using the “Human Galectin-3 Platinum ELISA” kit (GmbH, Austria) on the Stat Fax 2100 (USA) immunofermentive plate analyzer. The fluorescent AGEs in plasma were analysed by quantitative autofluorescence (fluorimeter Hoefer DQ 2000, USA) with fixed spectrum of excitation at 460 nm with 20 % quinine solution as a standard with results expressed with conversion to glycated albumin.

Results. AGE (mean 1.579 [0.884, 2.796]) and galectin-3 (mean 8.542 [2.72, 17.73]) levels increased in 83.3 % (25 patients) and 23.3 % (7 patients) respectively. The level of galectin-3 increased with age (by 33.18 %, p<0.05), while the level of AGE did not have significant changes. Levels of AGE and galectin-3 increased with a decrease in GFR (by 18.9 %, p<0.05 and 18.44 %, p<0.05, respectively). The level of AGE and serum creatinine correlated to GFR (r=0.25, p<0.05 and r=-0.22, p<0.05, respectively), while the level of galectin-3 correlated to GFR (r=-0.16, p<0.05). Intake of irbesartan reduced the level of galectin-3 (by 21.66 %) and AGE (by 4.9 %). The level of serum creatinine was decreased (by 4.89 %) and GFR was increased (by 6.3 %) compared with the intake of ACE inhibitors (by 2.9 % and 1.02 %, respectively).

Discussion. The results showed changes in AGE with a decrease in GFR in patients with CHF and AF, which makes it possible to consider AGE, as a marker of cardiorenal syndrome and makes it promising to further study it. Galectin-3 showed itself not only as a diagnostic marker, but also as a dynamic (positive effect of using irbesartan). Irbesartan had comparable clinical efficacy with ACE inhibitors in patients with CHF and AF.

Conclusions. Among patients with CHF and AF, the level of AGE was increased 83.3 % of patients, galectin-3 - in 23.3 %. Depending on the age, priority was given to galectin-3 (an increase of 33.18 %, p<0.05). The levels of AGE and galectin-3 depends of GFR and were increased (by 18.9 % and 18.44 %, p <0.05 respectively). The use of irbesartan showed a more significant positive effect on the level of galectin-3 and AGE with GFR in the range <60≥30 ml/min/1.73 m2.


Keywords


glycation end products; galectin-3; glomerular filtration rate; chronic heart failure; atrial fibrillation

Full Text:

PDF

References


Gajjala, P. R., Fliser, D., Speer, T., Jankowski, V., Jankowski, J. (2015). Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease. Nephrology Dialysis Transplantation, 30 (11), 1814–1824. doi: 10.1093/ndt/gfv048

Ahmed, N., Thornalley, P. J. (2009). The role of advanced glycation end products in the pathogenesis of diabetes complications. RMJ, 9, 642–650.

Spasov, A. A., Rashchenko, A. I., Brigadirova, A. A. (2016). Optimization of method in vitro for re-glycation activity of compounds investigation. VolgSMU, 1 (57), 30–32.

Lancefield, T. F., Patel, S. K., Freeman, M., Velkoska, E., Wai, B., Srivastava, P. M. et. al. (2016). The Receptor for Advanced Glycation End Products (RAGE) Is Associated with Persistent Atrial Fibrillation. PLOS ONE, 11 (9), e0161715. doi: 10.1371/journal.pone.0161715

Kikuchi, Y., Kobayashi, S., Hemmi, N., Ikee, R., Hyodo, N., Saigusa, T. et. al. (2004). Galectin-3-positive cell infiltration in human diabetic nephropathy. Nephrology Dialysis Transplantation, 19 (3), 602–607. doi: 10.1093/ndt/gfg603

Tseluiko, V. I., Vashakidze, Z. S., Motylevskaya, T. V., Opolonskaya, N. A. (2012). Galectin-3 in patients with atrial fibrillation. Ukrainian Cardiology Journal, 3, 45–49.

Gyamdzhan, K. A., Drapkina, O. M., Maksimov, M. L. (2014). Galectin-3: clinical and prognostic value in patients with chronic heart failure. Heart failure, 82 (1), 51–55.

DeFilippi, C. R., Felker, G. M. (2010). Galectin-3 in Heart Failure – Linking Fibrosis, Remodelling and Progression. European Cardiology Review, 6 (2), 33–36. doi: 10.15420/ecr.2010.6.2.33

De Boer, R. A., Yu, L., van Veldhuisen, D. J. (2010). Galectin-3 in Cardiac Remodeling and Heart Failure. Current Heart Failure Reports, 7 (1), 1–8. doi: 10.1007/s11897-010-0004-x

Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S. et. al. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 37 (27), 2129–2200. doi: 10.1093/eurheartj/ehw128

Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B. et. al. (2016). 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 37 (38), 2893–2962. doi: 10.1093/eurheartj/ehw210

Eknoyan, G., Lameire, N., Eckardt, K.-U. et. al. (2013). KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements, 3 (1), 5–150.

Rebrova, O. Yu. (2002). Statistical analysis of medical data. The use of the application package statistics. Moscow: MediaSphere, 312.

Luevano-Contreras, C., Chapman-Novakofski, K. (2010). Dietary Advanced Glycation End Products and Aging. Nutrients, 2 (12), 1247–1265. doi: 10.3390/nu2121247

Semba, R. D., Ferrucci, L., Sun, K., Beck, J., Dalal, M., Varadhan, R. et. al. (2009). Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women. Aging Clinical and Experimental Research, 21 (2), 182–190. doi: 10.1007/bf03325227

Hartog, J. W. L., Voors, A. A., Bakker, S. J. L., Smit, A. J., van Veldhuisen, D. J. (2007). Advanced glycation end-products (AGEs) and heart failure: Pathophysiology and clinical implications. European Journal of Heart Failure, 9 (12), 1146–1155. doi: 10.1016/j.ejheart.2007.09.009

Willemsen, S., Hartog, J. W. L., Heiner-Fokkema, M. R., van Veldhuisen, D. J., Voors, A. A. (2011). Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome. Heart Failure Reviews, 17 (2), 221–228. doi: 10.1007/s10741-010-9225-z

Reznik, E. V., Storozchakov, G. I. (2009). The heart is ill – kidneys suffer: Cardiorenal Syndrome in Patients with Chronic Heart Failure. Therapeutics, 1, 27–35.

Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M. et. al. (2017). 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 136 (6), e137–e161. doi: 10.1161/cir.0000000000000509

Fomin, V. V. (2013). Angiotensin II receptor blockers and control of cardiorenal risk: position of irbesartan. Medical advice, 9, 34–38.




DOI: http://dx.doi.org/10.21303/2504-5679.2018.00542

Refbacks

  • There are currently no refbacks.




Copyright (c) 2018 Olexander Kuryata, Muhammad Muhammad, Olga Mytrokhina

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2504-5679 (Online), ISSN 2504-5660 (Print)